JP2004534788A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534788A5
JP2004534788A5 JP2003502981A JP2003502981A JP2004534788A5 JP 2004534788 A5 JP2004534788 A5 JP 2004534788A5 JP 2003502981 A JP2003502981 A JP 2003502981A JP 2003502981 A JP2003502981 A JP 2003502981A JP 2004534788 A5 JP2004534788 A5 JP 2004534788A5
Authority
JP
Japan
Prior art keywords
combination
optionally substituted
macrocyclic lactone
receptor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003502981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534788A (ja
JP4476623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/006278 external-priority patent/WO2002100148A2/en
Publication of JP2004534788A publication Critical patent/JP2004534788A/ja
Publication of JP2004534788A5 publication Critical patent/JP2004534788A5/ja
Application granted granted Critical
Publication of JP4476623B2 publication Critical patent/JP4476623B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003502981A 2001-06-08 2002-06-07 インスリン産生細胞移植片拒絶の処置または予防 Expired - Fee Related JP4476623B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
PCT/EP2002/006278 WO2002100148A2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Publications (3)

Publication Number Publication Date
JP2004534788A JP2004534788A (ja) 2004-11-18
JP2004534788A5 true JP2004534788A5 (enExample) 2005-12-22
JP4476623B2 JP4476623B2 (ja) 2010-06-09

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003502981A Expired - Fee Related JP4476623B2 (ja) 2001-06-08 2002-06-07 インスリン産生細胞移植片拒絶の処置または予防

Country Status (18)

Country Link
US (5) US20030003099A1 (enExample)
EP (1) EP1429845B1 (enExample)
JP (1) JP4476623B2 (enExample)
CN (1) CN1524002A (enExample)
AT (1) ATE424893T1 (enExample)
AU (1) AU2002320828B2 (enExample)
BR (1) BR0209319A (enExample)
CA (1) CA2445605A1 (enExample)
DE (1) DE60231522D1 (enExample)
ES (1) ES2322442T3 (enExample)
IL (1) IL158384A0 (enExample)
NO (1) NO20035434D0 (enExample)
NZ (1) NZ529044A (enExample)
PL (1) PL364359A1 (enExample)
PT (1) PT1429845E (enExample)
RU (1) RU2003136730A (enExample)
WO (1) WO2002100148A2 (enExample)
ZA (1) ZA200307893B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
NZ551308A (en) * 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
JP2008530024A (ja) * 2005-02-08 2008-08-07 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニスト／モジュレーターおよび免疫抑制剤の組み合わせ剤による、抗リンパ球抗体誘導
US20090191218A1 (en) * 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
ES2348701T3 (es) * 2005-05-11 2010-12-10 Loma Linda University Composiciones y mã‰todos para prevenir y tratar trastornos inflamatorios de mediaciã“n inmune.
PT1961734E (pt) * 2005-12-15 2011-10-06 Mitsubishi Tanabe Pharma Corp Composto de amina e sua utilização para fins médicos
AU2007224250B2 (en) * 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP2868743B1 (en) * 2006-09-28 2017-11-15 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering RNA
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
ES2653199T3 (es) * 2008-03-12 2018-02-06 Loma Linda University Vacunas de ADN y procedimientos de prevención de rechazo tras un trasplante
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
EP2356090B1 (en) * 2008-11-11 2017-07-05 Novartis AG Crystalline forms of fingolimod hcl
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CA2957078C (en) * 2009-06-30 2019-04-30 Lifescan, Inc Analyte testing methods and device for calculating basal insulin therapy
CN102483776A (zh) * 2009-06-30 2012-05-30 生命扫描苏格兰有限公司 用于糖尿病管理的系统和方法
IN2012DN02710A (enExample) * 2009-09-29 2015-09-11 Lifescan Scotland Ltd
EP2590098B1 (en) * 2010-02-25 2014-11-05 Lifescan Scotland Limited Analyte testing method and system with high and low blood glucose trends notification
US10813987B2 (en) 2011-09-23 2020-10-27 Loma Linda University Method for inducing a tolerogenic immune response
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ES2204944T3 (es) * 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Similar Documents

Publication Publication Date Title
RU2009143333A (ru) Производные аминодигидротиазина, замещенные циклической группой
JP2004516314A5 (enExample)
JP2005506352A5 (enExample)
JP2008514732A5 (enExample)
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
RU2013107007A (ru) Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение
JP2006501181A5 (enExample)
JP2009532453A5 (enExample)
KR20180132939A (ko) 암 치료를 위한 조합 요법
JP2008510691A5 (enExample)
JP2013532652A5 (enExample)
JP2005533775A5 (enExample)
JP2004531544A5 (enExample)
JP2008535902A5 (enExample)
RU2003136730A (ru) Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата
RU2006137794A (ru) Химические составы, композиции и способы их использования
CN1277553A (zh) 血管生成促进剂和血管生成增效剂
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2009511508A5 (enExample)
JP2012519691A5 (enExample)
RU99112577A (ru) Новое применение 1,3-пропандиольных производных
EP2077846A4 (en) BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF
RU2012110380A (ru) Новое производное 5-фторурацила
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2022505268A5 (enExample)